Navigation Links
Oncothyreon reports first quarter 2009 financial results
Date:5/14/2009

$ (2,472) $ (5,217) ------------ ------------ ------------ ------------ Basic and diluted loss per share $ (0.13) $ (0.26) ------------ ------------ Weighted average number of common shares outstanding (in thousands) 19,492 19,486 ------------ ------------ Oncothyreon Inc. Consolidated Balance Sheets Data (in thousands) (unaudited) March 31, December 31, 2009 2008 Cash, cash equivalents and short term investments................................. $ 15,430 $ 19,166 Total assets................................. $ 21,207 $ 24,971 Total long-term liabilities.................. $ 389 $ 393 Stockholders' equity......................... $ 18,661 $ 20,717 Common shares outstanding (in thousands)..... 19,492 19,492


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Oncothyreon regains compliance with NASDAQ listing requirements
2. Oncothyreon to present at Invest Northwest 2009
3. Oncothyreon reports full year and fourth quarter 2008 financial results
4. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
5. Oncothyreon to present at BIO CEO & Investor Conference 2009
6. Oncothyreon reports third quarter 2008 financial results
7. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
8. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
9. Oncothyreon to present at BIO Investor Forum 2008
10. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
11. Oncothyreon announces prioritization plan for development programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , September 2, 2014 Persistence ... Membrane Technology in Pharmaceutical, Biopharma and Life Sciences: ... by 2019" the global membrane technology market for pharmaceutical, biopharma and ... 2014 and is expected to grow at a CAGR ... estimated value of USD 10,886.0 million in 2019. ...
(Date:9/2/2014)... Myriant Corporation, a global renewable chemicals ... agreement with Azelis Group, a specialty chemicals distribution ... in the Nordics, Benelux, France, Iberia, Italy, the ... industrial and base chemicals markets. , “As a ... chemical portfolio with extensive distribution networks providing Myriant ...
(Date:9/2/2014)... , Sept. 2, 2014  Xencor, Inc. (NASDAQ: ... developing engineered monoclonal antibodies for the treatment of ... today announced the appointment of Debra Zack ... the appointment of Lloyd Rowland , senior ... "Debra,s expertise in biologics clinical ...
(Date:9/2/2014)... 2, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the ... orders consist of three large odour control systems for waste ... "These orders are consistent with the market resurgence in ... , President and CEO. "After a difficult period of restraint ... beginning to see sales growth. Our lower cost structure, technology ...
Breaking Biology Technology:Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 2Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 3Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 4Global Membrane Technology Market Will Reach $10,886.0 Million in 2019: Persistence Market Research 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3
... Inc. (Nasdaq: IDEV ) today announced that ... Food and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a ... only product approved by the FDA for therapy ... the,urinary bladder. VALSTAR was removed from the ...
... Extracranial Resources Benefits Baltimore ... Area and ... Cancer Center at Johns Hopkins Medicine is adding an Elekta,Synergy(R) S ... Johns Hopkins aims to fight cancer with,both intracranial and extracranial resources ...
... Balance of Year, SAN DIEGO, Aug. 17 ... Noble Financial Equity,Conference at 11:30 a.m. EDT on Tuesday, ... South Carolina. William Spencer, Imagenetix,s Chief Executive Officer ... and prospects for the,Company. Commenting on the prospects, Mr. ...
Cached Biology Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 2Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 3Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007 2
(Date:9/2/2014)... hot oven, you rapidly pull your hand away. Although ... and responding to such painful stimuli, they are still ... made a surprising discovery about the role of a ... built a structural model of the molecule. These discoveries, ... help direct new strategies to treat pain in people. ...
(Date:9/1/2014)... of research shows an association between TV viewing and ... a new Cornell University study points out that not ... people to eat twice as much as other programs! ... while snacking your mouth will see more action too!" ... article just published in the Journal of the ...
(Date:9/1/2014)... of the U.S. diet showed some modest improvement in ... reduction in the consumption of unhealthy trans fats, but ... rich and the poor. , , An unhealthy diet ... cancers. Eating a healthy diet is an important part ... population trends in diet quality is important because it ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Can action movies make you fat? 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... picture in this kind of article , A detailed ... in activating the Epstein Barr Virus in human cells has ... Laboratory (EMBL) and the Institut de Virologie Moléculaire et Structurale ... in Grenoble. , Like Sleeping Beauty, the Epstein Barr Virus ...
... leading plant science centre have uncovered a gene that could ... able to cope with the changing world climate. Researchers funded ... the John Innes Centre in Norwich have identified the gene ... changes in the length of the day. This is key ...
... avian flu conference last fall believe there is little chance ... enough vaccine or antiviral medication to stop a bird flu ... be spread easily from human to human, according to a ... of the survey will be published in the June 2006 ...
Cached Biology News:Waking a sleeping virus 2Growing crops to cope with climate change 2Medical experts: US unlikely to have enough vaccines to stop avian flu 2